Medicus Pharma Ltd
MDCX2.390USD
-0.180-7.00%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
32.07MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Medicus Pharma Ltd Unternehmen
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets. Its subsidiaries include SkinJect, Inc, and Medicus Pharma Inc. The Company’s wholly owned subsidiary, SkinJect, Inc (SkinJect), is focused on commercializing a novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumor cells. The Company’s wholly owned subsidiaries are focused on the development of a drug delivery system using a dissolvable microneedle array for the treatment of certain skin cancers. The Company investigates opportunities across all therapeutic areas where an unmet need exists for improved patient safety and efficacy. The Company is actively exploring expanding its drug development pipeline through qualified and accretive acquisitions and partnerships.
Unternehmensinformationen
BörsenkürzelMDCX
Name des UnternehmensMedicus Pharma Ltd
IPO-datumOct 11, 2023
CEODr. Raza Bokhari, M.D.
Anzahl der mitarbeiter12
WertpapierartOrdinary Share
GeschäftsjahresendeOct 11
Addresse100 King Street West
StadtTORONTO
BörseNASDAQ Capital Market Consolidated
LandCanada
PostleitzahlM5X 1A4
Telefon17323003046
Websitehttps://medicuspharma.com/
BörsenkürzelMDCX
IPO-datumOct 11, 2023
CEODr. Raza Bokhari, M.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Raza Bokhari, M.D.
Dr. Raza Bokhari, M.D.
Executive Chairman, of the Board, Chief Executive Officer
Executive Chairman, of the Board, Chief Executive Officer
793.17K
--
Mr. James P. Quinlan
Mr. James P. Quinlan
Chief Financial Officer
Chief Financial Officer
129.15K
--
Ms. Carolyn F Bonner
Ms. Carolyn F Bonner
President
President
18.91K
--
Mr. William L. (Bill) Ashton
Mr. William L. (Bill) Ashton
Independent Director
Independent Director
1.25K
--
Mr. Andrew A. Smith
Mr. Andrew A. Smith
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Faisal Mehmud, M.D.
Dr. Faisal Mehmud, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Edward J. Brennan, Jr., M.D.
Dr. Edward J. Brennan, Jr., M.D.
Chief Scientific Officer, Head of Research and Development Program
Chief Scientific Officer, Head of Research and Development Program
--
--
Mr. Frank W. Lavelle
Mr. Frank W. Lavelle
Independent Director
Independent Director
--
--
Dr. Sara R. May, Ph.D.
Dr. Sara R. May, Ph.D.
Director
Director
--
--
Mr. Barry Fishman, CPA
Mr. Barry Fishman, CPA
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Raza Bokhari, M.D.
Dr. Raza Bokhari, M.D.
Executive Chairman, of the Board, Chief Executive Officer
Executive Chairman, of the Board, Chief Executive Officer
793.17K
--
Mr. James P. Quinlan
Mr. James P. Quinlan
Chief Financial Officer
Chief Financial Officer
129.15K
--
Ms. Carolyn F Bonner
Ms. Carolyn F Bonner
President
President
18.91K
--
Mr. William L. (Bill) Ashton
Mr. William L. (Bill) Ashton
Independent Director
Independent Director
1.25K
--
Mr. Andrew A. Smith
Mr. Andrew A. Smith
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Faisal Mehmud, M.D.
Dr. Faisal Mehmud, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Jul 19
Aktualisiert: Sat, Jul 19
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Velocity Fund Partners LP
18.29%
215 Capital Togo PHL Fund I, LP
12.55%
Interchange Capital Partners LLC
9.96%
Armistice Capital LLC
7.95%
Hathaway (John)
5.03%
Other
46.23%
Aktionäre
Aktionäre
Anteil
Velocity Fund Partners LP
18.29%
215 Capital Togo PHL Fund I, LP
12.55%
Interchange Capital Partners LLC
9.96%
Armistice Capital LLC
7.95%
Hathaway (John)
5.03%
Other
46.23%
Aktionärstypen
Aktionäre
Anteil
Corporation
30.84%
Individual Investor
13.82%
Investment Advisor
11.73%
Hedge Fund
7.95%
Other
35.66%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
21
10.18M
63.87%
+72.74K
2025Q1
19
10.07M
84.39%
+1.61M
2024Q4
12
8.43M
77.76%
+1.48M
2024Q3
8
6.05M
68.59%
+2.33M
2024Q2
7
4.05M
50.15%
+329.10K
2024Q1
9
3.82M
47.35%
+3.82M
2023Q4
9
3.82M
47.35%
+3.82M
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Velocity Fund Partners LP
2.91M
18.29%
+75.00K
+2.64%
Jun 02, 2025
215 Capital Togo PHL Fund I, LP
2.00M
12.55%
--
--
Jun 02, 2025
Interchange Capital Partners LLC
1.66M
10.43%
+204.71K
+14.05%
Mar 31, 2025
Armistice Capital LLC
1.27M
7.95%
--
--
Jun 02, 2025
Hathaway (John)
800.95K
5.03%
--
--
Jun 02, 2025
Bokhari (Raza)
793.17K
4.98%
--
--
Jun 02, 2025
Melani (Kenneth)
334.41K
2.1%
-75.00K
-18.32%
Jun 02, 2025
Quinlan (James P)
129.15K
0.81%
--
--
Jun 02, 2025
Brennan (Edward Joseph JR)
86.50K
0.54%
--
--
Jun 02, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
